A virus, plant shutdown, FDA consent decree, Carl Icahn, and finally Sanofi-Aventis--what a ride it's been for Genzyme. But the rollercoaster has yet to come to a stop. Sanofi CEO Christopher Viehbacher says changes are coming to Genzyme as a result of the merger. "It wouldn't be credible to say there aren't going to be some cost savings along the way,'' he tells the Boston Globe. Story
